IS5260A - Uppleystar sertralín samsetningar - Google Patents

Uppleystar sertralín samsetningar

Info

Publication number
IS5260A
IS5260A IS5260A IS5260A IS5260A IS 5260 A IS5260 A IS 5260A IS 5260 A IS5260 A IS 5260A IS 5260 A IS5260 A IS 5260A IS 5260 A IS5260 A IS 5260A
Authority
IS
Iceland
Prior art keywords
formulations
dissolved sertraline
sertraline
dissolved
sertraline formulations
Prior art date
Application number
IS5260A
Other languages
English (en)
Inventor
Thomas Friesen Dwayne
Max Herbig Scott
Mysore Shanker Ravi
Blair West James
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5260(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5260A publication Critical patent/IS5260A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS5260A 1997-07-01 1999-11-19 Uppleystar sertralín samsetningar IS5260A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Publications (1)

Publication Number Publication Date
IS5260A true IS5260A (is) 1999-11-19

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5260A IS5260A (is) 1997-07-01 1999-11-19 Uppleystar sertralín samsetningar

Country Status (34)

Country Link
EP (1) EP0999829A1 (is)
JP (1) JP2000514100A (is)
KR (1) KR100366373B1 (is)
CN (1) CN1261794A (is)
AP (1) AP1192A (is)
AR (3) AR015917A1 (is)
AU (1) AU742535B2 (is)
BG (1) BG103918A (is)
BR (1) BR9810739A (is)
CA (1) CA2290974C (is)
CO (1) CO4940495A1 (is)
DZ (1) DZ2548A1 (is)
EA (1) EA002481B1 (is)
HN (1) HN1998000102A (is)
HR (1) HRP980377A2 (is)
HU (1) HUP0002236A3 (is)
ID (1) ID23429A (is)
IL (1) IL133076A (is)
IS (1) IS5260A (is)
MA (1) MA24587A1 (is)
NO (1) NO996520L (is)
OA (1) OA11243A (is)
PA (1) PA8454301A1 (is)
PE (1) PE97199A1 (is)
PL (1) PL337804A1 (is)
SK (1) SK181099A3 (is)
TN (1) TNSN98124A1 (is)
TR (1) TR199903297T2 (is)
TW (1) TW550087B (is)
UA (1) UA67741C2 (is)
UY (1) UY25071A1 (is)
WO (1) WO1999001120A1 (is)
YU (1) YU68299A (is)
ZA (1) ZA985708B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
CN101631593B (zh) * 2007-03-12 2014-08-13 帝斯曼知识产权资产管理有限公司 化妆品组合物
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
US20130035344A1 (en) * 2009-12-29 2013-02-07 Kowa Co., Ltd. Pharmaceutical composition for oral administration
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736B (zh) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
IL133076A (en) 2003-12-10
CO4940495A1 (es) 2000-07-24
ZA985708B (en) 2000-01-10
CA2290974A1 (en) 1999-01-14
PA8454301A1 (es) 2000-09-29
BR9810739A (pt) 2000-09-12
YU68299A (sh) 2002-06-19
ID23429A (id) 2000-04-20
NO996520D0 (no) 1999-12-28
AP1192A (en) 2003-07-23
SK181099A3 (en) 2000-07-11
BG103918A (en) 2000-07-31
EA199900962A1 (ru) 2000-08-28
AR040279A2 (es) 2005-03-23
JP2000514100A (ja) 2000-10-24
AU7544898A (en) 1999-01-25
MA24587A1 (fr) 1998-12-31
AR040280A2 (es) 2005-03-23
UA67741C2 (uk) 2004-07-15
KR20010013365A (ko) 2001-02-26
AR015917A1 (es) 2001-05-30
EA002481B1 (ru) 2002-06-27
OA11243A (en) 2003-07-24
HUP0002236A3 (en) 2003-12-29
KR100366373B1 (ko) 2003-01-14
TNSN98124A1 (fr) 2005-03-15
AU742535B2 (en) 2002-01-03
DZ2548A1 (fr) 2003-02-08
PL337804A1 (en) 2000-09-11
EP0999829A1 (en) 2000-05-17
NO996520L (no) 2000-02-29
HRP980377A2 (en) 1999-04-30
HN1998000102A (es) 1999-01-08
HUP0002236A2 (hu) 2003-08-28
TW550087B (en) 2003-09-01
AP9801280A0 (en) 1998-06-30
CA2290974C (en) 2004-04-27
IL133076A0 (en) 2001-03-19
TR199903297T2 (xx) 2000-07-21
WO1999001120A1 (en) 1999-01-14
UY25071A1 (es) 2000-12-29
PE97199A1 (es) 1999-10-05
CN1261794A (zh) 2000-08-02

Similar Documents

Publication Publication Date Title
MA24473A1 (fr) Formulations
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
DE59802860D1 (de) Desinfektionsmittel
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
DK0853945T3 (da) Flydende gonadotropinholdige formuleringer
ID23299A (id) Formulasi-formulasi farmasi
DE69828330D1 (de) Aktiviertes Protein C Formulierungen
ATE227074T1 (de) Mikrokapsel-formulierungen
DE69812475T2 (de) Photoresistzusammensetzung
NO980546D0 (no) Farmasöytiske midler
DE69809717D1 (de) Konzentrierte desinfektionsmittel
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
ATE232683T1 (de) Mikrokapsel-formulierungen
DE69800779D1 (de) Photopolymerisierbare Zusammensetzung
DE69809633D1 (de) Photoresistzusammensetzung
NO995147D0 (no) Kontrastmidler
ID16781A (id) Formulasi-formulasi farmasi
NO20002590D0 (no) Formuleringer omfattende oppløst paroxetin
NO996520L (no) Oppløste sertralinblandinger